NCT06162169View on ClinicalTrials.gov

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 25, 2023

Primary Completion Date

February 20, 2024

Study Completion Date

February 20, 2024

Conditions
Healthy Subjects
Interventions
DRUG

JAB-21822

JAB-21822 was administered orally

DRUG

Itraconazole

Itraconazole was administered orally

DRUG

Omeprazole

Omeprazole was administered orally

DRUG

Midazolam , Rosuvastatin calcium and digoxin

Midazolam , Rosuvastatin calcium and digoxin was administered orally

DRUG

Rifampicin

Rifampicin was administered orally

Trial Locations (1)

102206

Beijing GoBroad Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY